Ryan Specialty Holdings (RYAN) Earnings Date & Reports

Key Takeaways

• Ryan Specialty reported third quarter 2026 total revenue of $790.0 million, up 4.7% from $754.6 million a year earlier, though slightly below consensus estimates.
• Adjusted (non-GAAP) diluted earnings per share came in at $0.51, beating the analyst consensus of $0.49 by $0.02.
• GAAP net income rose 40.6% to $88.0 million, with diluted earnings per share of $0.29.
• Organic revenue growth was 4.0% for the quarter, while Adjusted EBITDAC grew 3.8% and Adjusted Diluted EPS rose 8.5%.
• The company maintained its full-year 2026 mid-single-digit organic revenue growth guidance and updated its Adjusted EBITDAC margin outlook to a modest decline versus 2025.
• For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages available for RYAN.
• You can also discover automated strategies and market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Ryan Specialty Holdings is a leading international specialty insurance firm serving brokers, agents, and carriers. Its third quarter 2026 results carry added weight because they arrived against the company's toughest year-over-year comparison, offering investors a clearer read on how durable its growth engine remains in a more competitive specialty market. The quarter tested both revenue momentum and margin discipline, two pillars of the company's investment thesis. With organic growth slowing modestly from prior peaks and expense management under scrutiny, the report served as a key checkpoint on whether Ryan Specialty could keep expanding profitability while continuing to invest in talent and platform capabilities.

Reported Results

For the third quarter ended September 30, 2026, Ryan Specialty reported total revenue of $790.0 million, an increase of 4.7% from $754.6 million in the prior-year period. Organic revenue growth was 4.0% for the quarter. GAAP net income climbed 40.6% to $88.0 million, up from $62.6 million a year earlier, translating to basic earnings per share of $0.30 and diluted earnings per share of $0.29.

On an adjusted (non-GAAP) basis, diluted earnings per share reached $0.51, exceeding the consensus estimate of $0.49 by $0.02. Revenue, however, came in slightly below the consensus figure of roughly $793.6 million. Adjusted EBITDAC (earnings before interest, taxes, depreciation, amortization, and change in contingent consideration) grew 3.8%, while Adjusted Diluted EPS rose 8.5%. The company noted its Adjusted EBITDAC margin was down only 30 basis points year to date, reflecting disciplined expense management.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking specialty insurance names like Ryan Specialty, it offers a structured way to surface comparable setups and momentum signals across the sector.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around Ryan Specialty reflected a cautious market environment, with the company's shares trading lower over the trailing three- and twelve-month periods. The results presented a mixed picture for investors: an adjusted earnings beat underscored resilient profitability and cost control, while the modest revenue miss relative to consensus highlighted softer top-line momentum than analysts had modeled. The company's maintained mid-single-digit organic growth guidance for 2026 signaled confidence in its core franchise, though the updated outlook for a modestly lower Adjusted EBITDAC margin pointed to continued investment-related cost pressure. Net-net, the quarter reinforced the narrative of a durable, scalable platform performing steadily through a more challenging specialty insurance cycle.

Forward Outlook and Key Factors to Monitor

Ryan Specialty maintained its full-year 2026 guidance for mid-single-digit organic revenue growth, a signal that management expects its broking and underwriting businesses to keep expanding despite a tougher competitive backdrop. At the same time, the company updated its outlook to expect an Adjusted EBITDAC margin that is down modestly for 2026 compared to the prior year, reflecting ongoing investments in talent and platform capabilities.

Investors will want to monitor several themes in the quarters ahead. First, watch whether organic revenue growth can reaccelerate or stabilize as prior-year comparisons ease. Second, keep an eye on margin trends, since continued hiring and platform spending could pressure profitability even as revenue grows. Third, the pace of capital returns matters: the company returned roughly $173.7 million to shareholders in the quarter and still has buyback capacity remaining, which could support the stock if execution stays steady.

Finally, broader specialty insurance conditions—including pricing, catastrophe activity, and carrier underwriting appetite—will shape demand for Ryan Specialty's products and services. The company ended the quarter with $168.8 million in cash and $3.7 billion in outstanding debt principal, so balance-sheet management and interest costs remain relevant factors to track.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations